Get started
Author

Gabriella Camboni

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
2011 · Ezia Bello, Gennaro Colella, et al. · Cancer Research · 143
PDF
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma
2004 · D.I Jodrell, T.R.J Evans, et al. · European Journal of Cancer · 130
A work in progress: The clinical development of histone deacetylase inhibitor
2008 · Silvia Marsoni, Giovanna Damia, et al. · Epigenetics · 80
PDF
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex
2000 · C. Sessa, G. Capri, et al. · Annals of Oncology · 76
Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test.
1985 · G Basilisco, A Bozzani, et al. · Gut · 56
Oral naloxone antagonizes loperamide-induced delay of orocecal transit
1987 · G. Basilisco, G. Camboni, et al. · Digestive Diseases and Sciences · 54
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma
2001 · P. Borchmann, R. Schnell, et al. · Annals of Oncology · 52
PDF
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
2003 · Peter Borchmann, Franck Morschhauser, et al. · PubMed · 51
Orocecal transit delay in obese patients
1989 · G. Basilisco, G. Camboni, et al. · Digestive Diseases and Sciences · 47
The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
2012 · Ezia Bello, Giulia Taraboletti, et al. · Molecular Cancer Therapeutics · 45
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly
2000 · L.K. Dawson, D.I. Jodrell, et al. · European Journal of Cancer · 42
Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer
2001 · A.H. Calvert, H. Thomas, et al. · European Journal of Cancer · 41
Lactose malabsorption and intolerance in Italians
1986 · A. Bozzani, R. Penagini, et al. · Digestive Diseases and Sciences · 38
A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
2001 · S Faivre, E Raymond, et al. · PubMed · 37
A phase I study of the trinuclear platinum compound, BBR�3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer
2004 · Charlie Gourley, James Cassidy, et al. · Cancer Chemotherapy and Pharmacology · 27
Repeatability of lactulose hydrogen breath test in subjects with normal or prolonged orocecal transit
1988 · G. Camboni, G. Basilisco, et al. · Digestive Diseases and Sciences · 25
Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger‐Ellison syndrome and antral G‐cell hyperfunction
1994 · B. ANNIBALE, G. DELLE FAVE, et al. · Alimentary Pharmacology & Therapeutics · 18
P-523 Phase II trial of BBR3464, a novel, bifunctional platinum analog, as second line treatment of non-small cell lung cancer patients
2003 · Giorgio Scagliotti, Silvia Novello, et al. · Lung Cancer · 12
A phase I/II trial of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL)
2004 · G. Camboni, L. Fayad, et al. · Journal of Clinical Oncology · 3
Phase II trial of BBR3464, a novel, bifunctional platinum analog, in advanced but favorable out-come, Non Small Cell Lung Cancer patients
2001 · G. Scagliotti, L. Crinò, et al. · European Journal of Cancer · 3
Abstract 595: E-3810 antitumor activity in human xenografts expressing different levels of FGF receptor 1
2011 · Gennaro Colella, Giovanna Damia, et al. · Cancer Research · 2
Abstract 1367: The dual selective VEGFR-FGFR kinases inhibitor E-3810 decreases tumor perfusion and inhibits tumor growth: an analysis using dynamic contrast-enhanced magnetic resonance imaging
2010 · Francis Bichat, Xavier Tizon, et al. · Cancer Research · 2
Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A)
1988 · M. Colle, E. Ruedas, et al. · European Journal of Clinical Pharmacology · 2
Intragastric and intraoesophagel pH monitoring in duodenal ulcer patients: effect of the new histamine H2-receptor antagonist ramixotidine
1989 · M. Molgora, G. Basilisco, et al. · European Journal of Clinical Pharmacology · 1
Loperamide and oro‐caecal transit delay [letter]
1986 · G Basilisco, G Camboni, et al. · British Journal of Clinical Pharmacology · 1
PDF
Works count: 57
Citation count: 989
H-index: 17
I10-index: 18
Year
Topic
Type